DOCSLIB.ORG

ARK Investment Management LLC Form 13F-HR Filed 2019-07-30

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ARK Investment Management LLC Form 13F-HR Filed 2019-07-30 SECURITIES AND EXCHANGE COMMISSION FORM 13F-HR Initial quarterly Form 13F holdings report filed by institutional managers Filing Date: 2019-07-30 | Period of Report: 2019-06-30 SEC Accession No. 0001144204-19-036628 (HTML Version on secdatabase.com) FILER ARK Investment Management LLC Mailing Address Business Address 3 EAST 28TH STREET, 7TH 3 EAST 28TH STREET, 7TH CIK:1697748| IRS No.: 464309299 | State of Incorp.:DE | Fiscal Year End: 1231 FLOOR FLOOR Type: 13F-HR | Act: 34 | File No.: 028-17768 | Film No.: 19984667 NEW YORK NY 10016 NEW YORK NY 10016 212-426-7040 Copyright © 2019 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE OMB Number: 3235-0006 COMMISSION Expires: July 31, 2015 Washington, D.C. 20549 Estimated average burden hours per response: 23.8 FORM 13F FORM 13F COVER PAGE Report for the Calendar Year or Quarter Ended: 06-30-2019 Check here if Amendment: ☐ Amendment Number: This Amendment (Check only one.): ☐ is a restatement. ☐ adds new holdings entries. Institutional Investment Manager Filing this Report: Name: ARK Investment Management LLC Address: 3 East 28th Street, 7th Floor New York, NY 10016 Form 13F File Number: 028-17768 The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Kellen Carter Title: Chief Compliance Officer Phone: 212-426-7040 Signature, Place, and Date of Signing: /s/ Kellen Carter New York, NEW YORK 07-30-2019 [Signature] [City, State] [Date] Report Type (Check only one.): ☒ 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) ☐ 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) ☐ 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) Form 13F Summary Page Report Summary: Number of Other Included Managers: 0 Form 13F Information table Entry Total: 235 Form 13F Information table Value Total: 3969269 (thousands) List of Other Included Managers: Provide a numbered list of the name(s) and Form 13F file number(s) of all institutional investment managers with respect to which this report is filed, other than the manager filing this report. [If there are no entries in this list, state "NONE" and omit the column headings and list entries.] NONE Copyright © 2019 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0006 Washington, D.C. 20549 Expires: July 31, 2015 Estimated average burden FORM 13F hours per response: 23.8 FORM 13F INFORMATION TABLE COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8 VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE 2U INC Common Stock 90214J101 52,845 1,403,952 SH SOLE 1,130,073 22,946 250,933 3D SYSTEMS CORP Common Stock 88554D205 2,058 226,193 SH SOLE 226,193 0 0 ADOBE SYSTEMS INC Common Stock 00724F101 8,058 27,347 SH SOLE 27,347 0 0 AEROVIRONMENT INC Common Stock 008073108 10,319 181,776 SH SOLE 100,928 0 80,848 ALIBABA GROUP HOLDING-SP ADR ADR 01609W102 25,783 152,159 SH SOLE 113,595 9,534 28,850 ALIGN TECHNOLOGY INC Common Stock 016255101 3,240 11,837 SH SOLE 11,837 0 0 ALLEGHENY TECHNOLOGIES INC Common Stock 01741R102 50 1,983 SH SOLE 1,983 0 0 ALPHABET INC-CL C Common Stock 02079K107 1,712 1,584 SH SOLE 1,558 0 0 AMAZON.COM INC Common Stock 023135106 21,176 11,183 SH SOLE 8,824 0 2,359 AMETEK INC Common Stock 031100100 533 5,871 SH SOLE 5,871 0 0 ANSYS INC Common Stock 03662Q105 3,521 17,190 SH SOLE 17,190 0 0 APPLE INC Common Stock 037833100 17,714 89,502 SH SOLE 65,283 333 23,886 APTIV PLC Common Stock G6095L109 6,122 75,737 SH SOLE 72,994 2,743 0 ARCONIC INC Common Stock 03965L100 497 19,234 SH SOLE 19,234 0 0 ARCTURUS THERAPEUTICS LTD Common Stock 03969T109 9,481 1,004,368 SH SOLE 1,004,368 0 0 ARKEMA SA Misc. 786477208 45 480 SH SOLE 480 0 0 ARRK CORP Common Stock J0198N101 371 396,233 SH SOLE 396,233 0 0 AUDIOCODES LTD Common Stock M15342104 475 30,696 SH SOLE 30,696 0 0 AUTODESK INC Common Stock 052769106 5,351 32,847 SH SOLE 32,847 0 0 BAIDU INC - SPON ADR ADR 056752108 74,167 631,960 SH SOLE 463,291 46,376 121,401 BERTRANDT AG Closed-End Fund 09249Y107 331 4,666 SH SOLE 4,666 0 0 BITCOIN INVESTMENT TRUST Open-End Fund 389637109 25,790 1,704,557 SH SOLE 723,176 452,291 529,090 BLUEBIRD BIO INC Common Stock 09609G100 13,781 108,341 SH SOLE 50,111 17,034 41,007 CAMTEK LTD Common Stock M20791105 415 49,129 SH SOLE 49,129 0 0 CARPENTER TECHNOLOGY Common Stock 144285103 49 1,018 SH SOLE 1,018 0 0 CELGENE CORP Common Stock 151020104 0 0 SH SOLE 0 0 0 CELLCOM ISRAEL LTD Common Stock M2196U109 319 110,305 SH SOLE 110,305 0 0 CELLECTIS - ADR ADR 15117K103 17,210 1,103,186 SH SOLE 970,054 115,566 15,225 CERAGON NETWORKS LTD Common Stock M22013102 385 131,354 SH SOLE 131,354 0 0 CERUS CORP Common Stock 157085101 47,731 8,493,022 SH SOLE 6,703,613 97,172 1,692,237 CHECK POINT SOFTWARE TECH Common Stock M22465104 477 4,127 SH SOLE 4,127 0 0 COGNEX CORP Common Stock 192422103 3,434 71,574 SH SOLE 71,574 0 0 COMPUGEN LTD Common Stock M25722105 32,627 8,496,641 SH SOLE 8,283,152 70,360 143,129 CRISPR THERAPEUTICS AG Common Stock H17182108 128,317 2,724,349 SH SOLE 2,079,857 167,959 473,500 CYBERARK SOFTWARE LTD/ISRAEL Common Stock M2682V108 538 4,206 SH SOLE 4,206 0 0 DANEL (ADIR YEOSHUA) LTD Common Stock M27013107 571 8,788 SH SOLE 8,788 0 0 DEERE & CO Common Stock 244199105 2,109 12,727 SH SOLE 12,727 0 0 EASTMAN CHEMICAL CO Common Stock 277432100 48 616 SH SOLE 616 0 0 EASTMAN KODAK CO Common Stock 277461406 50 20,712 SH SOLE 20,712 0 0 EDITAS MEDICINE INC Common Stock 28106W103 119,943 4,848,148 SH SOLE 3,757,979 288,386 795,739 ELBIT SYSTEMS LTD Common Stock M3760D101 2,874 19,221 SH SOLE 19,221 0 0 EVOGENE LTD Common Stock M4119S104 327 202,990 SH SOLE 202,990 0 0 EXONE CO/THE Common Stock 302104104 21,478 2,304,554 SH SOLE 1,923,735 0 380,819 FARO TECHNOLOGIES INC Common Stock 311642102 479 9,117 SH SOLE 9,117 0 0 FOAMIX PHARMACEUTICALS LTD Common Stock M46135105 349 146,745 SH SOLE 146,745 0 0 GENERAL ELECTRIC CO Common Stock 369604103 441 42,044 SH SOLE 42,044 0 0 Copyright © 2019 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document GENERAL MOTORS CO Common Stock 37045V100 1,751 45,449 SH SOLE 45,449 0 0 GILAT SATELLITE NETWORKS LTD Common Stock M51474118 460 54,388 SH SOLE 54,388 0 0 HEXCEL CORP Common Stock 428291108 61 757 SH SOLE 757 0 0 HILAN LTD Common Stock 421962101 1,423 17,566 SH SOLE 17,566 0 0 HORTONWORKS INC Common Stock 440894103 0 0 SH SOLE 0 0 0 HP INC Common Stock 40434L105 2,610 125,529 SH SOLE 125,529 0 0 HUBSPOT INC Common Stock 443573100 7,767 45,550 SH SOLE 45,550 0 0 ILLUMINA INC Common Stock 452327109 197,892 537,531 SH SOLE 420,465 30,390 86,030 INCYTE CORP Common Stock 45337C102 11,107 130,737 SH SOLE 130,737 0 0 INOVIO PHARMACEUTICALS INC Common Stock 45773H201 11,628 3,955,017 SH SOLE 3,955,017 0 0 INTELLIA THERAPEUTICS INC Common Stock 45826J105 134,941 8,243,165 SH SOLE 6,769,387 523,553 939,650 INVITAE CORP Common Stock 46185L103 221,444 9,423,157 SH SOLE 7,431,910 369,271 1,618,367 IONIS PHARMACEUTICALS INC Common Stock 462222100 10,140 157,773 SH SOLE 157,773 0 0 ITURAN LOCATION AND CONTROL Common Stock M6158M104 404 13,417 SH SOLE 13,417 0 0 JD.COM INC-ADR ADR 47215P106 4,462 147,325 SH SOLE 147,325 0 0 KAMADA LTD Common Stock M6240T109 452 81,874 SH SOLE 81,874 0 0 KONINKLIJKE DSM NV Closed-End Fund 09662E109 4 445 SH SOLE 445 0 0 LENDINGCLUB CORP Common Stock 52603A208 338,818 20,659,636 SH SOLE 17,212,729 271,344 3,175,563 LENDINGTREE INC Common Stock 52603B107 41,590 99,017 SH SOLE 62,126 9,278 27,503 MATERIALISE NV-ADR ADR 57667T100 54,513 2,792,678 SH SOLE 2,515,416 40,865 236,397 MATRIX IT LTD Common Stock 576853105 729 35,995 SH SOLE 35,995 0 0 MEDIDATA SOLUTIONS INC Common Stock 58471A105 599 6,623 SH SOLE 0 6,412 0 MELLANOX TECHNOLOGIES LTD Common Stock M51363113 457 4,132 SH SOLE 4,132 0 0 MERCADOLIBRE INC Common Stock 58733R102 8,973 14,667 SH SOLE 10,759 3,500 352 MICROSOFT CORP Common Stock 594918104 1,363 10,172 SH SOLE 10,172 0 0 NANO DIMENSION LTD - ADR ADR 63008G104 382 796,459 SH SOLE 796,459 0 0 NANOSTRING TECHNOLOGIES INC Common Stock 63009R109 107,017 3,526,095 SH SOLE 3,340,959 173,099 10,135 NETFLIX INC Common Stock 64110L106 43,207 117,628 SH SOLE 89,431 9,430 18,603 NICE LTD ADR 653656108 499 3,641 SH SOLE 3,641 0 0 NOVA MEASURING INSTRUMENTS Common Stock M7516K103 442 17,266 SH SOLE 17,266 0 0 NVIDIA CORP Common Stock 67066G104 175,960 1,071,425 SH SOLE 823,598 59,057 187,833 ORBOTECH LTD Common Stock M75253100 0 0 SH SOLE 0 0 0 ORGANOVO HOLDINGS INC Common Stock 68620A104 11,052 21,132,709 SH SOLE 21,062,140 70,569 0 PACIFIC BIOSCIENCES OF CALIF Common Stock 69404D108 0 0 SH SOLE 0 0 0 PARTNER COMMUNICATIONS CO ADR 70211M109 472 112,426 SH SOLE 112,426
Load more

Recommended publications
  • Market Cap Close ADV 1598 67Th Pctl 745,214,477.91 $ 23.96
    Market Cap Close ADV 1598 67th Pctl $ 745,214,477.91 $ 23.96 225,966.94 801 33rd Pctl $ 199,581,478.89 $ 10.09 53,054.83 2399 Ticker_ Listing_ Effective_ Revised Symbol Security_Name Exchange Date Mkt Cap Close ADV Stratum Stratum AAC AAC Holdings, Inc. N 20160906 M M M M-M-M M-M-M AAMC Altisource Asset Management Corp A 20160906 L M L L-M-L L-M-L AAN Aarons Inc N 20160906 H H H H-H-H H-H-H AAV Advantage Oil & Gas Ltd N 20160906 H L M H-L-M H-M-M AB Alliance Bernstein Holding L P N 20160906 H M M H-M-M H-M-M ABG Asbury Automotive Group Inc N 20160906 H H H H-H-H H-H-H ABM ABM Industries Inc. N 20160906 H H H H-H-H H-H-H AC Associated Capital Group, Inc. N 20160906 H H L H-H-L H-H-L ACCO ACCO Brand Corp. N 20160906 H L H H-L-H H-L-H ACU Acme United A 20160906 L M L L-M-L L-M-L ACY AeroCentury Corp A 20160906 L L L L-L-L L-L-L ADK Adcare Health System A 20160906 L L L L-L-L L-L-L ADPT Adeptus Health Inc. N 20160906 M H H M-H-H M-H-H AE Adams Res Energy Inc A 20160906 L H L L-H-L L-H-L AEL American Equity Inv Life Hldg Co N 20160906 H M H H-M-H H-M-H AF Astoria Financial Corporation N 20160906 H M H H-M-H H-M-H AGM Fed Agricul Mtg Clc Non Voting N 20160906 M H M M-H-M M-H-M AGM A Fed Agricultural Mtg Cla Voting N 20160906 L H L L-H-L L-H-L AGRO Adecoagro S A N 20160906 H L H H-L-H H-L-H AGX Argan Inc N 20160906 M H M M-H-M M-H-M AHC A H Belo Corp N 20160906 L L L L-L-L L-L-L AHL ASPEN Insurance Holding Limited N 20160906 H H H H-H-H H-H-H AHS AMN Healthcare Services Inc.
    [Show full text]
  • Advancing Cell Therapeutic Products for Clinical Use
    Advancing cell therapeutic products for clinical use 1 Proprietary data of Pluristem Therapeutics Inc. Forward Looking Statement This presentation concerning Pluristem Therapeutics may include forward- looking statements which represent Pluristem Therapeutics' expectations or beliefs regarding future events. I caution that such statements involve risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements. Consequently, all such forward-looking statements are qualified by the cautionary language and risk factors set forth in Pluristem Therapeutics' periodic and other reports filed with the SEC. There can be no assurance that the actual results, events or developments referenced in such forward-looking statements will occur or be realized. Pluristem Therapeutics assumes no obligation to update these forward- looking statements to reflect actual results, changes in assumptions or changes in factors affecting such forward-looking statements. www.pluristem.com 2 Proprietary data of Pluristem Therapeutics Inc. Corporate Overview • Cell therapy company (NasdaqCM: PSTI, TASE: PSTI) • Using off-the-shelf, placenta-derived cells to achieve both local and systemic therapeutic effects – no tissue matching needed • First-in-class 3D cell culturing technology allowing for efficient, controlled production of multiple cell products in commercial quantities – “the process is the product” • Active with regulators in the U.S., EU, S. Korea, Australia & Israel • Demonstrated safety and efficacy in 3 clinical studies (two Phase I and one Phase I/II study) 3 Proprietary data of Pluristem Therapeutics Inc. Financial Overview • Market Cap: ~ $200 million • Cash and marketable securities: $41 million (March, 2015) • No debt • Net burn: ~ $23 million • 165 employees (16 PhD, 4 MD) • IP Ownership: over 40 granted patents and ~150 pending applications 4 Proprietary data of Pluristem Therapeutics Inc.
    [Show full text]
  • Market Cap Close ADV
    Market Cap Close ADV 1598 67th Pctl $745,214,477.91 $23.96 225,966.94 801 33rd Pctl $199,581,478.89 $10.09 53,054.83 2399 Listing_ Revised Ticker_Symbol Security_Name Exchange Effective_Date Mkt Cap Close ADV Stratum Stratum AAC AAC Holdings, Inc. N 20160906 M M M M-M-M M-M-M Altisource Asset Management AAMC Corp A 20160906 L M L L-M-L L-M-L AAN Aarons Inc N 20160906 H H H H-H-H H-H-H AAV Advantage Oil & Gas Ltd N 20160906 H L M H-L-M H-M-M AB Alliance Bernstein Holding L P N 20160906 H M M H-M-M H-M-M ABG Asbury Automotive Group Inc N 20160906 H H H H-H-H H-H-H ABM ABM Industries Inc. N 20160906 H H H H-H-H H-H-H AC Associated Capital Group, Inc. N 20160906 H H L H-H-L H-H-L ACCO ACCO Brand Corp. N 20160906 H L H H-L-H H-L-H ACU Acme United A 20160906 L M L L-M-L L-M-L ACY AeroCentury Corp A 20160906 L L L L-L-L L-L-L ADK Adcare Health System A 20160906 L L L L-L-L L-L-L ADPT Adeptus Health Inc. N 20160906 M H H M-H-H M-H-H AE Adams Res Energy Inc A 20160906 L H L L-H-L L-H-L American Equity Inv Life Hldg AEL Co N 20160906 H M H H-M-H H-M-H AF Astoria Financial Corporation N 20160906 H M H H-M-H H-M-H AGM Fed Agricul Mtg Clc Non Voting N 20160906 M H M M-H-M M-H-M AGM A Fed Agricultural Mtg Cla Voting N 20160906 L H L L-H-L L-H-L AGRO Adecoagro S A N 20160906 H L H H-L-H H-L-H AGX Argan Inc N 20160906 M H M M-H-M M-H-M AHC A H Belo Corp N 20160906 L L L L-L-L L-L-L ASPEN Insurance Holding AHL Limited N 20160906 H H H H-H-H H-H-H AHS AMN Healthcare Services Inc.
    [Show full text]
  • Biolinerx Ltd. (Translation of Registrant’S Name Into English) ______
    SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2018 _______________________ BioLineRx Ltd. (Translation of registrant’s name into English) _______________________ 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) _______________________ Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☑ Form 40-F ☐ Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934: Yes ☐ No ☑ The registrant hereby announces that it has entered into an employment agreement with Hillit Mannor Shachar, M.D., MBA, M.S.F.S., to serve as its new Vice President Business Development, effective April 1, 2018. Dr. Shachar will be responsible for BioLineRx’s business development, commercialization of assets and pipeline strategy. Dr. Shachar joins BioLineRx with over 15 years of experience in senior business development, corporate development and venture capital positions in the life sciences field. Her recent experience has included service as Vice President Business Development of Pluristem Therapeutics (NASDAQ:PSTI), a leading developer of placenta-based cell therapy products, and Director of New Business Development at West Pharmacuetical Services. In addition, Dr. Shachar has served at several life science companies and venture capital funds, including Apax Partners, Nektar Therapeutics, Orex Computed Radiography, Kodak and Transpharma Medical.
    [Show full text]
  • Submission Data File
    Date: 05/27/2016 04:48 PM Vintage Project: v441042 Form Type: 6-K Client: v441042_Pointer Telocation Ltd_6-K Submission Data File General Information Form Type* 6-K Contact Name Chico Kim Contact Phone 866-683-5252 Filer File Number Filer CIK* 0000920532 [Pointer Telocation Ltd] (Pointer Telocation Ltd) Filer CCC* ********** Confirming Copy No Notify via Website only No Return Copy No SROS* NASD Period* 05-27-2016 (End General Information) Document Information File Count* 32 Document Name 1* v441042_6k.htm Document Type 1* 6-K Document Description 1 6-K Document Name 2* v441042_ex99-1.htm Document Type 2* EX-99.1 Document Description 2 Exhibit 99.1 Document Name 3* v441042_ex99-2.htm Document Type 3* EX-99.2 Document Description 3 Exhibit 99.2 (End Document Information) Notifications Notify via Website only No E-mail 1 [email protected] (End Notifications) Date: 05/27/2016 04:48 PM Vintage Project: v441042 Form Type: 6-K Client: v441042_Pointer Telocation Ltd_6-K File: v441042_6k.htm Type: 6-K Pg: 1 of 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2016 Commission File Number: 001-13138 Pointer Telocation Ltd. (Translation of registrant's name into English) 14 Hamelacha Street, Rosh Ha'ayin, Israel 4809133 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
    [Show full text]
  • PLURISTEM THERAPEUTICS INC. (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 001-31392 PLURISTEM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 98-0351734 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) MATAM Advanced Technology Park, Building No. 5, Haifa, Israel 31905 (Address of principal executive offices) (Zip Code) Registrant's telephone number 011-972-74-7107259 Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of each exchange on which registered Common Stock, par value $0.00001 Nasdaq Capital Market Securities registered pursuant to Section 12(g) of the Act: None. (Title of class) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • 2018 Annual Report TAT Technologies
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to _____________ ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report ……………….. Commission file number: 0-16050 TAT TECHNOLOGIES LTD. (Exact name of Registrant as specified in its charter and translation of Registrant’s name into English) Israel (Jurisdiction of incorporation or organization) P.O. Box 80, Gedera 7075002, Israel (Address of principal executive offices) Securities registered or to be registered pursuant to Section 12(b) of the Act: Title of each class Name of each exchange on which registered Ordinary Shares, NIS 0.90 Par Value NASDAQ Global Market Securities registered or to be registered pursuant to Section 12(g) of the Act: None Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None Indicate the number of outstanding shares of each of the issuer’s classes of capital or Common stock as of the close of the period covered by the annual report: Ordinary Shares, par value NIS 0.90 per share…………… 8,874,696 (as of December 31, 2018) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]
  • Life Sciences in Israel
    STATE OF ISRAEL Ministry of Industry Trade and Labor Investment Promotion Center Inspiration Invention Innovation Life Sciences in Israel www.investinisrael.gov.il Table of Contents .......................................... 3 Israel: A Powerhouse of Opportunities ............................................................ 3 Israel’s Life Science Sectors Medical Devices ........................................................................ 4 Healthcare IT ............................................................................ 4 BioPharmaceutical .................................................................... 7 Israel’s Biomedical Engineering - ................................................... 11 Spotlight on Stem Cell Research ....................................... 15 Israel’s Life Sciences Competitive Edge ..................................................................... 19 Government Support 2 Life Sciences in Israel Israel: A Powerhouse of Opportunities Why Israel’s Life Sciences Over the last decade, Israel has introduced a wealth of groundbreaking More than 1,000 Life and valuable innovations in Life Sciences. Israel’s Life Sciences sector Sciences Companies - is supported by a strong foundation of academic excellence, including Biopharma and Medical some of the world’s leading research institutes, renowned R&D Devices facilities and cutting-edge medical centers. Bolstered by a highly skilled Over 1/3 of LS Start-Ups workforce, a flourishing high-tech environment, and an entrepreneurial already generate revenue
    [Show full text]
  • Alphabetical Listing by Company Name
    FOREIGN COMPANIES REGISTERED AND REPORTING WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION December 31, 2015 Alphabetical Listing by Company Name COMPANY COUNTRY MARKET 21 Vianet Group Inc. Cayman Islands Global Market 37 Capital Inc. Canada OTC 500.com Ltd. Cayman Islands NYSE 51Job, Inc. Cayman Islands Global Market 58.com Inc. Cayman Islands NYSE ABB Ltd. Switzerland NYSE Abbey National Treasury Services plc United Kingdom NYSE - Debt Abengoa S.A. Spain Global Market Abengoa Yield Ltd. United Kingdom Global Market Acasti Pharma Inc. Canada Capital Market Acorn International, Inc. Cayman Islands NYSE Actions Semiconductor Co. Ltd. Cayman Islands Global Market Adaptimmune Ltd. United Kingdom Global Market Adecoagro S.A. Luxembourg NYSE Adira Energy Ltd. Canada OTC Advanced Accelerator Applications SA France Global Market Advanced Semiconductor Engineering, Inc. Taiwan NYSE Advantage Oil & Gas Ltd. Canada NYSE Advantest Corp. Japan NYSE Aegean Marine Petroleum Network Inc. Marshall Islands NYSE AEGON N.V. Netherlands NYSE AerCap Holdings N.V. Netherlands NYSE Aeterna Zentaris Inc. Canada Capital Market Affimed N.V. Netherlands Global Market Agave Silver Corp. Canada OTC Agnico Eagle Mines Ltd. Canada NYSE Agria Corp. Cayman Islands NYSE Agrium Inc. Canada NYSE AirMedia Group Inc. Cayman Islands Global Market Aixtron SE Germany Global Market Alamos Gold Inc. Canada NYSE Alcatel-Lucent France NYSE Alcobra Ltd. Israel Global Market Alexandra Capital Corp. Canada OTC Alexco Resource Corp. Canada NYSE MKT Algae Dynamics Corp. Canada OTC Algonquin Power & Utilities Corp. Canada OTC Alianza Minerals Ltd. Canada OTC Alibaba Group Holding Ltd. Cayman Islands NYSE Allot Communications Ltd. Israel Global Market Almaden Minerals Ltd.
    [Show full text]
  • Fidelity® Nasdaq Composite Index® Fund
    Fidelity® Nasdaq Composite Index® Fund Semi-Annual Report May 31, 2021 Contents Note to Shareholders 3 Investment Summary 4 Schedule of Investments 6 Financial Statements 85 Notes to Financial 89 Statements Shareholder Expense 97 Example Board Approval of 98 Investment Advisory Contracts and Management Fees Liquidity Risk 106 Management Program To view a fund’s proxy voting guidelines and proxy voting record for the 12-month period ended June 30, visit http://www.fidelity.com/proxyvotingresults or visit the Securities and Exchange Commission’s (SEC) web site at http://www.sec.gov. You may also call 1-800-544-8544 to request a free copy of the proxy voting guidelines. Nasdaq®, OMX®, NASDAQ OMX®, Nasdaq Composite®, and The Nasdaq Stock Market®, Inc. are registered trademarks of The NASDAQ OMXGroup, Inc. (which with its Affiliates are the Corporations) and are licensed for use by Fidelity. The product has not been passed on by the Corporations as to its legality or suitability. The product is not issued, endorsed or sold by the Corporations. The Corporations make no warranties and bear no liability with respect to shares of the product. Standard & Poor’s, S&P and S&P 500 are registered service marks of The McGraw-Hill Companies, Inc. and have been licensed for use by Fidelity Distributors Corporation. Other third-party marks appearing herein are the property of their respective owners. All other marks appearing herein are registered or unregistered trademarks or service marks of FMR LLC or an affiliated company. © 2021 FMR LLC. All rights reserved. This report and the financial statements contained herein are submitted for the general information of the shareholders of the Fund.
    [Show full text]
  • Fidelity® Nasdaq Composite Index® Fund
    Quarterly Holdings Report for Fidelity® Nasdaq Composite Index® Fund February 28, 2021 EIF-QTLY-0421 1.814098.116 Schedule of Investments February 28, 2021 (Unaudited) Showing Percentage of Net Assets Common Stocks – 99.7% Shares Value COMMUNICATION SERVICES – 16.7% Diversified Telecommunication Services – 0.2% Alaska Communication Systems Group, Inc. 34,501 $ 112,818 Anterix, Inc. (a) 7,844 331,252 ATN International, Inc. 7,220 351,470 Bandwidth, Inc. (a) (b) 12,082 1,913,306 Cogent Communications Group, Inc. (b) 25,499 1,526,115 Consolidated Communications Holdings, Inc. (a) 21,768 114,500 Iridium Communications, Inc. (a) 77,117 2,954,352 Liberty Global PLC: Class A (a) 112,326 2,766,028 Class B (a) 327 7,521 Class C (a) 204,417 4,967,333 Liberty Latin America Ltd.: Class A (a) 17,405 190,933 Class C (a) 105,781 1,159,360 ORBCOMM, Inc. (a) 54,925 419,078 Radius Global Infrastructure, Inc. (a) (b) 37,222 460,808 Sify Technologies Ltd. sponsored ADR (a) (b) 7,275 22,916 Vonage Holdings Corp. (a) 142,421 1,882,806 19,180,596 Entertainment – 2.5% Activision Blizzard, Inc. 429,734 41,086,868 Bilibili, Inc. ADR (a) (b) 99,200 12,496,224 Blue Hat Interactive Entertainment Technology (a) (b) 13,117 16,659 Chicken Soup For The Soul Entertainment, Inc. (a) 2,009 51,370 Cinedigm Corp. (a) 73,305 102,627 CuriosityStream, Inc. Class A (a) 24,573 426,833 DouYu International Holdings Ltd. ADR (a) 82,330 1,180,612 Electronic Arts, Inc.
    [Show full text]
  • Nasdaq Capital Market Friday, December 28, 2018 5:32 PM
    Nasdaq Capital Market Friday, December 28, 2018 5:32 PM Name Symbol Close 3PEA International TPNL 3.35 Abeona Therapeutics ABEO 7.02 Ability ABIL 2.02 Abraxas Petroleum AXAS 1.08 Acasti Pharma ACST 0.73 Accelerate Diagnostics AXDX 11.78 Acer Therapeutics ACER 18.25 Achieve Life Sciences ACHV 1.2 ACNB ACNB 38.73 Adamis Pharmaceuticals ADMP 2.1 Adesto Technologies IOTS 4.3 ADial Pharmaceuticals ADIL 5.55 ADMA Biologics ADMA 2.23 ADOMANI ADOM 0.25 Aehr Test Systems AEHR 1.44 Aerpio Pharmaceuticals ARPO 1.71 AEterna Zentaris AEZS 2.97 Aethlon Medical AEMD 1.52 Agenus AGEN 2.39 AGM Group Holdings AGMH 28.05 Airgain AIRG 10.04 AirMedia Group ADR AMCN 0.24 Air T AIRT 24.03 Akari Therapeutics ADR AKTX 1.63 Akers Biosciences AKER 1.27 Akoustis Technologies AKTS 4.79 Alberton Acquisition Cl A ALAC 9.8 Alberton Acquisition WT ALACW 0.12 Albireo Pharma ALBO 23.18 Aldeyra Therapeutics ALDX 8 Alithya Group Cl A ALYA 2.55 Alkaline Water WTER 3.24 Allegro Merger Rt ALGRR 0.3 Alliance MMA AMMA 0.17 Allied Healthcare Products AHPI 1.89 Alliqua BioMedical ALQA 2 Alta Mesa Resources AMR 1 Alta Mesa Resources WT AMRWW 0.08 Altus Midstream ALTM 7.75 AMCI Acquisition AMCIU 9.95 American Electric Technologies AETI 0.89 Ameri Holdings AMRH 0.17 Ameri Holdings WT AMRHW 0.03 Ames National ATLO 25.72 Anavex Life Sciences AVXL 1.52 Anixa Biosciences ANIX 4 Antares Pharma ATRS 2.63 Apollo Medical Holdings AMEH 20.73 Appliance Recycling Centers of ARCI 0.5 America Applied DNA Sciences APDN 0.38 Applied DNA Sciences WT APDNW ..
    [Show full text]